A Paradigm Shift to a Purpose-Driven Review System

The U.S. Food and Drug Administration (FDA) officially released its white paper, the "Rare Disease Framework Initiative," on October 14, 2026, which completely redesigns the development and regulation of rare disease treatments. The intent is to establish 'Fit-for-purpose' review criteria tailored to the characteristics of individual diseases, moving away from the existing one-size-fits-all standards. Regulatory reforms covering the entire lifecycle of therapeutics have been initiated, from preclinical participation stages and clinical design to quality control (CMC) and post-marketing confirmatory trials. This is a strategic measure to practically reflect the development environment for rare diseases, where the patient population is extremely small and natural history data are scarce.

Regulatory Leadership Change and Policy Normalization

This restructuring is part of a regulatory reset aimed at stabilizing the confusion in FDA regulatory policy and the leadership transition that has persisted over recent years. Controversy arose over the flexibility applied by the former director of CBER during the approval of Sarepta’s gene therapy Elevidys, and the strict standards imposed by subsequent hardline leadership caused significant confusion for the biotech industry and patient groups. Following the recent resignations of two hardline figures, the FDA is undertaking a structural reorganization to review controversial rejection decisions and strengthen review transparency. This is regarded as a key milestone for regulators to restore lost policy credibility and re-establish market predictability.

Expectation of Ending Wall Street's 'Guessing Game'

The investment industry expects this framework to be a turning point that significantly reduces the uncertainty in the new drug approval process. Joseph Schwartz, senior analyst at Leerink Partners, analyzed that "while the FDA is not lowering standards, it is helping to move the approval process away from a kind of guessing game." Just as the Orphan Drug Act and Priority Review Voucher (PRV) programs have stimulated biotech investment, this permanent regulatory framework will also facilitate capital inflow from institutional investors. The clarification of approval criteria could lead to a revaluation of companies like BioMarin and Ultragenyx, which hold rare pipelines.

Unmet Demand in the $240 Billion Market and Roadmap

Although there are approximately 30 million rare disease patients in the U.S., approved treatments exist for only 5% of these conditions, leaving a 95% unmet medical demand. As of 2026, the global orphan drug market size is estimated at approximately $243 billion and is projected to grow to over $330 billion in the early 2030s. The FDA plans to release its first specific regulatory recommendations in February 2027, following the collection of public comments from a hearing on October 28, 2026. Once the scope of recognized surrogate endpoints and biomarkers is specified, Big Pharma's license-in (L/I) and mergers and acquisitions (M&A) transactions are expected to expand significantly.